A

AFT Pharmaceuticals Ltd
NZX:AFT

Watchlist Manager
AFT Pharmaceuticals Ltd
NZX:AFT
Watchlist
Price: 2.84 NZD 1.43%
Market Cap: 297.8m NZD
Have any thoughts about
AFT Pharmaceuticals Ltd?
Write Note

AFT Pharmaceuticals Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

AFT Pharmaceuticals Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
A
AFT Pharmaceuticals Ltd
NZX:AFT
Other Current Liabilities
NZ$5.4m
CAGR 3-Years
-4%
CAGR 5-Years
16%
CAGR 10-Years
N/A
BLIS Technologies Ltd
NZX:BLT
Other Current Liabilities
NZ$35k
CAGR 3-Years
27%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Cannasouth Ltd
NZX:CBD
Other Current Liabilities
NZ$7.4k
CAGR 3-Years
N/A
CAGR 5-Years
-49%
CAGR 10-Years
N/A
Rua Bioscience Ltd
NZX:RUA
Other Current Liabilities
NZ$75.2k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Greenfern Industries Ltd
NZX:GFI
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

AFT Pharmaceuticals Ltd
Glance View

Market Cap
297.8m NZD
Industry
Pharmaceuticals

AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The firm's NasoSURF Nebuliser is in pilot scale production. The firm is focused on conducting clinical for Maxigesic oral dose forms. The firm is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.

AFT Intrinsic Value
4.72 NZD
Undervaluation 40%
Intrinsic Value
Price
A

See Also

What is AFT Pharmaceuticals Ltd's Other Current Liabilities?
Other Current Liabilities
5.4m NZD

Based on the financial report for Sep 30, 2024, AFT Pharmaceuticals Ltd's Other Current Liabilities amounts to 5.4m NZD.

What is AFT Pharmaceuticals Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
16%

Over the last year, the Other Current Liabilities growth was -54%. The average annual Other Current Liabilities growth rates for AFT Pharmaceuticals Ltd have been -4% over the past three years , 16% over the past five years .

Back to Top